

Title Page

Potent Inhibition of Alcohol Self-Administration in Alcohol-Preferring Rats by  
a Kappa Opioid Receptor Antagonist

*John R. Cashman\* and Marc R. Azar*

Human BioMolecular Research Institute, 5310 Eastgate Mall, San Diego, CA 92121, USA;

Behavioral Pharma Inc., 505 Coast Blvd. South, Suite 210, La Jolla, CA 92037, USA

**RECEIVED DATE (to be automatically inserted after your manuscript is accepted  
according to the journal)**

Running Title Page

**Running Title:** Potent alcohol cessation agents

Text page number: 25

Table number: 2

Figure number: 6

Scheme number: 1

References number: 62

Abstract words: 217

Introduction words: 740

Discussion words: 974

**Abbreviations:**  $\mu$ , mu opioid receptor;  $\delta$ , delta opioid receptor;  $\kappa$ , kappa opioid receptor; NOP, nociceptin opioid receptor; nor-BNI, Norbinaltorphimine; GNTI, 5'-Guanidinonaltrindole; JD<sub>Tic</sub>, (3*R*)-7-Hydroxy-N-[(2*S*)-1-[(3*R*,4*R*)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]-3-methylbutan-2-yl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; DIPEA, Diisopropylethylamine; BOP, (dimethylamino) phosphonium hexa-fluorophosphate; DCM, dichloromethane, ESI, electrospray ionization; BALs, Blood Alcohol Levels; SGPT, serum glutamic-pyruvic transaminase; SGOT, serum glutamic oxaloacetic transaminase.

**\*To whom correspondence should be addressed:**

**Dr. John R. Cashman**

**Human BioMolecular Research Institute**

**5310 Eastgate Mall**

**San Diego, CA 92121**

**Tel: 858-458-9305, Fax: 858-458-9311**

**E-Mail: [jcashman@hbri.org](mailto:jcashman@hbri.org)**

Abstract Page

**ABSTRACT**

A substituted aryl amide derivative of 6-naltrexamine, compound **5**, previously shown to be a potent kappa opioid receptor antagonist, was used to characterize the physicochemical properties and efficacy to decrease alcohol self-administration in alcohol-preferring rats (P-rats) and binge-like P-rats. Previous studies showed that compounds closely related to **5** possessed good blood-brain barrier penetrating properties. Pharmacokinetic studies showed that **5** had acceptable bioavailability. In contrast to other kappa receptor antagonists (i.e., nor-BNI) compound **5** showed favorable drug-like properties and further studies were done. Safety studies showed that **5** was not hepatotoxic at doses 200-fold greater than an efficacious dose. The effect of **5** or naltrexone on the hepatotoxicity of thiobenzamide was investigated. In contrast to naltrexone that exacerbated thiobenzamide-mediated hepatotoxicity, **5** was observed to be hepatoprotective. Based on the physicochemical properties of **5**, the compound was examined in rat animal models of alcohol self-administration. The inhibition of ethanol self-administration by **5** in alcohol-dependent or alcohol-nondependent P-rats trained to self-administer a 10 % (w/v) ethanol solution, utilizing operant techniques showed very potent efficacy (i.e., estimated ED<sub>50</sub> value 4-5 µg/kg). In a binge-like P-rat animal model, inhibition of alcohol self-administration by **5** had an estimated ED<sub>50</sub> value of 8 µg/kg. The results suggest that **5** is a potent drug-like kappa opioid receptor antagonist of utility in alcohol cessation medications development.



## Introduction

Ethanol overuse is a serious public health disorder with significant social and economic consequences. In 1994, naltrexone, a pure opioid  $\mu$  receptor antagonist with relatively low affinity for  $\delta$  and  $\kappa$  receptors and no abuse potential (Tabakoff et al., 1983) (compound **1**, Scheme 1) was approved by the United States FDA for treatment of alcoholism. A number of studies suggest that alcohol interacts with endogenous opioid systems (Grisel et al., 1995; Gianoulakis et al., 1996). Antagonizing opioid receptors decreases the effects of alcohol-mediated pleasure-inducing endogenous opioids. By attenuating the positive reinforcing effects of alcohol consumption, opioid receptor antagonists have direct effects on alcohol-seeking behavior (Pastor et al., 2006). A decrease in alcohol consumption by antagonism of opioid receptors suggests direct effects of this reinforcement system and animal studies have shown that mu ( $\mu$ )-, delta ( $\delta$ )- and kappa ( $\kappa$ )-opioid receptors contribute to alcohol-induced reinforcement (Herz, 1997; Ulm et al., 1995).

Based on a number of clinical studies, naltrexone is effective in decreasing alcohol consumption in heavy drinkers (Pettinati et al., 2006) and for treating alcoholism (Bouza et al., 2004; Anton et al., 1999). However, naltrexone is not successful in treating all alcoholics and adverse effects including intolerable nausea (Croop et al., 1997) and hepatotoxicity (Mason et al., 1999, Mitchell et al., 1987) confound treatment of patients with liver disease. However, most reports (Brewer and Wong, 2004; Sax et al., 1994; Yen et al., 2006) suggest that naltrexone itself does not cause clinically significant hepatotoxicity. Relatively low bioavailability of naltrexone (Anton et al., 1999) and possibly genetic variability of the opioid receptors (Oslin et al., 2006) may explain the less than consistent efficacy of naltrexone (Roozen et al., 2006).

Thiobenzamide is a well-characterized hepatotoxin that causes centrolobular necrosis (Hanzlik et al., 1980; Hanzlik et al., 1978) and requires S-oxidative metabolic bioactivation for full expression of its hepatotoxicity (Cashman and Hanzlik, 1981; Hanzlik and Cashman, 1983). Hepatotoxicity of toxic doses of thiobenzamide is maximal 24 h after administration and thus can provide an excellent acute model system to examine the effect of **5** or naltrexone on the exacerbation or protection of hepatotoxicity.

In contrast to naltrexone, a more selective kappa opioid receptor antagonist is nor-BNI. Nor-BNI is effective at decreasing alcohol self-administration in small animals (Walker et al., 2011; Walker and Koob, 2008). Despite its promise, nor-BNI possesses very long-lasting effects (Horan et al., 1992) and is possibly unstable to oxidation (Osa et al., 2007). Like other long-acting kappa opioid antagonists such as GNTI and JD<sub>Tic</sub>, nor-BNI has a very long time course of kappa opioid receptor antagonism (Munro et al., 2012). There is thus a need for a relatively fast-acting drug-like kappa opioid receptor antagonist that possesses appropriate pharmacokinetic and biodistribution properties consistent with a reversible drug.

Studies using rodent animal models have shown that naltrexone decreases alcohol self-administration (Benjamin et al., 1993; Stromberg et al., 2001), suggesting that these types of agents may prevent the reinforcing effects of alcohol consumption (Bouza et al., 2004). The alcohol preferring rat (P-rat) has been effectively used as a small animal model to study binge drinking (Li et al., 1987). In the P-rat, naltrexone (Ji et al., 2008; Gilpin et al., 2008; Biggs and Myers, 1997) and other opioids (Weiss et al., 1990) have been shown to be effective in decreasing alcohol self-administration. Nalmefene (Scheme 1), the 6-methylene analog of naltrexone, is a more potent  $\kappa$  opioid antagonist than naltrexone and is an effective antagonist of alcohol self-administration in outbred and P-rats (June et al., 2004; June et al., 1998).

Herein, we report on the evaluation of a potent  $\kappa$ -opioid antagonist as an alcohol self-administration cessation agent. Kappa opioid antagonists are anticipated to show a dual

action by inhibiting alcohol reinforcement and stimulating dopamine release to decrease craving. Compound **5** (Scheme 1) has been previously reported to decrease alcohol self-administration in Wistar rats. In this study, we extend the analysis to alcohol-preferring and binge-like P-rats. The results show that compound **5** is a very potent, relatively short-acting agent that decreases alcohol self-administration in P-rats and binge-like P rats. Compound **5** possesses good physicochemical properties and is very drug-like and, in contrast to naltrexone, protects from the hepatotoxicity of a potent hepatotoxin in rats. The rationale for our work was to develop a relatively short-acting drug-like  $\kappa$ -opioid antagonist by replacing the metabolically labile 6-keto moiety of naltrexone with an amide moiety, thus leading to an agent with potent pharmacological activity and potentially less hepatotoxicity.



## Methods

**Chemicals.** Naltrexone and nalmefene hydrochloride (compounds **1** and **2**, respectively) were obtained from Tyco Mallinckrodt (St. Louis, MO). Compound **3**, 17-Cyclopropylmethyl-3, 14 $\beta$ -dihydroxy-4, 5 $\alpha$ -epoxy-6 $\beta$ -[(4'-bromo)benzamido]morphinan-hydrochloride, and compound **5**, 17-Cyclopropylmethyl-3, 14 $\beta$ -dihydroxy-4, 5 $\alpha$ -epoxy-6 $\beta$ -[(4'-trimethylfluoro)benzamido]morphinan-hydrochloride were synthesized as previously described (Ghirmai et al., 2009) (Scheme 1).

Diisopropylethylamine (DIPEA), (dimethylamino) phosphonium hexa-fluorophosphate (BOP), HBF<sub>4</sub>, Pd(OAc)<sub>2</sub>, tetrabutylammonium hydroxide, thiobenzamide, heparin and Supersac were obtained from Sigma-Aldrich Chemical Company (St. Louis, MO) and were used as received. All of the solvents and buffers used were obtained in the highest grade commercially available from VWR (San Diego, CA).

**General Procedures.** Synthetic chemical reactions were run under a positive pressure of nitrogen with magnetic stirring at ambient temperature using oven-dried glassware unless otherwise indicated. Silica gel (230-400 mesh) was used for column chromatography. Dichloromethane (DCM) was dried by filtration through a column of neutral alumina and stored over activated 4 Å molecular sieves under nitrogen prior to use. All other solvents and reagents were used as received. <sup>1</sup>H NMR spectra were recorded at 300.0 MHz on a Varian Mercury 300 instrument. Chemical shifts were reported in ppm ( $\delta$ ) relative to CDCl<sub>3</sub> at 7.26 ppm. NMR spectra were recorded in CDCl<sub>3</sub>. Mass spectra were obtained with a Hitachi spectrometer operating in the ESI mode. Analytical purities were

determined by reverse phase HPLC using a Hitachi D2500 Hitachi Chromato-integrator, an L-6000 Hitachi pump and an L-4200 UV-vis Hitachi detector (285 nm) using a reverse phase system (5  $\mu$ m x 4.6 mm x 250 mm). The mobile phase was 20% 0.05 M tetrabutylammonium hydroxide and 80% methanol using isocratic elution at a flow rate of 1 mL/min. Analytical work for the pharmacokinetic studies was done at Microconstants, Inc., (San Diego, CA).

**Animals.** Animal work was conducted in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by the National Institutes of Health. Formal approval to conduct the experiments was obtained from the Institutional Animal Care and Use Committees (IACUCs) of the Human BioMolecular Research Institute and Behavioral Pharma, Inc. Animals were assigned randomly to experimental groups, allowed to acclimatize to the facilities for 1 week, and fed commercial rat chow and sterile distilled water *ad libitum*. For the studies with thiobenzamide, male Sprague Dawley rats weighing 300-400 g from Harlan (San Jose, CA) were used. For pharmacokinetic studies, cannulated male Sprague Dawley rats (Harlan) weighing 250-300 g at the time of the experiment were housed individually and maintained in a temperature-controlled environment on a 12h:12h light cycle (off 7:30 am: on 7:30 pm). Except during testing, animals were given free access to food and water. Animals administered compounds via the oral route were deprived of food 10 h before the experiment. For toxicology studies, compound **5** was administered to male Sprague Dawley rats weighing 300-350 g (Harlan). Twenty-four h after the last dose of **5**, animals were killed, blood was obtained, centrifuged and serum was separated and frozen for analysis of serum clinical chemistry at IDEXX Laboratories (Sacramento, CA). For

alcohol self-administration studies, male alcohol-preferring Wistar rats (P-rats) 225-249 g were obtained from the University of Indiana (Indianapolis, IN) and were housed in groups of two or three and maintained in a temperature-controlled environment on a 12h:12h light cycle (off 7:30 am: on 7:30 pm). Except during behavioral testing, animals were given free access to food and water.

### Chemical Synthesis.

**6- $\beta$ -(4'-Trifluoromethyl-2',3',5',6'-tetradeutrio)benzamido-14-hydroxy-17-(cyclopropylmethyl)nordesmorphine, compound 4.** Compound **4** (Scheme 1) was synthesized by combining  $\beta$ -naltrexamine and 4-CF<sub>3</sub>-benzoic acid-d<sub>4</sub> and BOP dissolved in anhydrous DCM followed by addition of DIPEA. After removal of the ester at the 3-position by treatment with potassium carbonate, **4** was obtained in quantitative yield and converted to its hydrochloride salt. The requisite 4-CF<sub>3</sub>-benzoic acid-d<sub>4</sub> was obtained following a literature procedure for a non-deuterated analog (Watson et al., 2008). A mixture of K<sub>2</sub>CO<sub>3</sub> (624 mg, 4.5 mmol, 1.5 equiv.), DCPD x HBF<sub>4</sub> (73.2 mg, 0.12 mmol, 4% mol) and Pd(OAc)<sub>2</sub> (13.5 mg, 0.06 mmol, 2% mol) were placed in an 8-dram vial. The vial was sealed with a septum and purged with Ar. A solution of 4-chloro-trifluoromethyl-toluene-d<sub>4</sub> (554 mg, 3 mmol) in DMSO (3 mL) and H<sub>2</sub>O (108  $\mu$ L, 108 mg, 6 mmol, 2 equiv.) was added via syringe. An atmosphere of CO was added to the vial and purged three times and run for 15 h at 100 °C under a CO atmosphere. The mixture was cooled and diluted with 0.25 M NaOH aq. (65 mL) and extracted with DCM (2 x 25 mL). The aqueous layer was neutralized with 3 M HCl (10 mL) and extracted with Et<sub>2</sub>O (3 x 50 mL). The combined organic material was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and

evaporated to give 4-CF<sub>3</sub>-benzoic acid-d<sub>4</sub> as a white solid, 550 mg, in 94% yield.

Compound **4-d<sub>4</sub>** was obtained following a previously reported procedure (Ghirmai et al., 2008). β-Naltrexamine (100 mg, 0.29 mmol), 4-CF<sub>3</sub>-benzoic acid-d<sub>4</sub> (113.3 mg, 0.584 mmol, 2 equiv.) and BOP (258 mg, 0.584 mmol, 2 equiv.) was placed in anhydrous DCM (4 mL) and DIPEA (152 μL, 0.876 mmol, 3 equiv.) was added and the reaction was stirred overnight at rt to afford the ester-amide. After purification by flash chromatography (100% EtOAc) the ester-amide was dissolved in methanol and potassium carbonate was added. The mixture was stirred at rt for 3 hr and potassium carbonate was removed by filtration and the product was purified by PTLC (CHCl<sub>3</sub>/MeOH) 20/1 to obtain in quantitative yield the desired product. The purity was > 98% on the basis of HPLC and LCMS.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.13 – 0.18 (m, 2H), 0.53 – 0.59 (m, 2H), 0.81 – 0.92 (m, 1H), 1.39 – 1.62 (m, 3H), 1.66 – 1.74 (m, 1H), 1.89 – 2.0 (m, 1H), 2.17 – 2.26 (m, 2H), 2.39 (d, J = 6.3 Hz, 2H), 2.65 (d, J = 9.9 Hz, 2H), 3.04 (d, J = 13.4 Hz, 1H), 3.16 (d, J = 5.2 Hz, 1H), 3.64 (d, J = 11.0 Hz, 1H), 4.08 – 4.18 (m, 2H), 4.63 (d, J = 5.24 Hz, 1H), 6.52 (d, J = 8.0 Hz, 1H), 6.67 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 9.0 Hz, 1H). ESI/MS *m/z* = 518.95 [M+H]

**Pharmacokinetic Studies.** The night before the oral pharmacokinetic study, the animals were fasted. Groups of two jugular cannulated rats were administered **5** hydrochloride by the i.v. route of administration (20 or 50 μg/kg, 1 ml/kg) or the oral route of administration (200 μg/kg, 2 ml/kg) in isotonic saline. For the i.v. study of **5**, blood was

taken at 5, 15, 30, 60, 120, 240 mins and 6 and 10 hours. For the oral study, blood was taken at 15, 30, 60, 120, 240 mins and 6 and 10 hours. Blood was combined with 2 IUs of heparin and immediately cooled to 4 °C. Separated plasma was brought to a pH of 10 with ammonium hydroxide, 400 pg/ml of **4** was added as an internal standard and extracted with hexane/methyl-tert-butyl ether (3:1, v:v). After centrifugation at 13,000 rpm for 5 min, the organic fraction was collected and the solvent was removed with a stream of argon. The residue was reconstituted in water:acetonitrile:formic acid (80:20:0.1, v:v) and run isocratically in 0.1% formic acid in water, 0.1% formic acid in acetonitrile (60:40) using a Waters Acquity instrument and Waters XEVO tandem quadrupole detector (Waters, Milford, MA). An aliquot was analyzed by RP-HPLC using a Synergi Polar RP column (2.1 mm x 150 mm, 4 µm) maintained at 45°C. The mobile phase was nebulized using heated nitrogen in a Z-spray source/interface set to electrospray positive mode. The ionized compounds were detected using MS/MS and both compounds **4** and **5** had retention times of 2.7 min in the LCMS experiment. The standard curve was run between 20-20,000 pg/ml. The calibration curves were obtained by fitting the in-transformed peak height ratios of compound **4/5** and their log-transformed standard concentrations to an appropriate regression equation using MassLynx software (Waters). Pharmacokinetic data was determined using an in-house Excel Macro program for pharmacokinetic parameters.

**In Vivo Hepatototoxicology Studies.** Thiobenzamide was administered i.p. as a very fine suspension in corn oil (2 mmol/kg, 274 mg/kg, 4 ml/kg). Naltrexone hydrochloride (500 µg/kg, 1 ml/kg, i.p.) was administered in sterile saline. Compound **5** hydrochloride (20

$\mu\text{g}/\text{kg}$ , 1 ml/kg, i.p.) was administered in sterile saline. On the day of the experiment, groups of six animals each were administered thiobenzamide or vehicle as a challenge dose. Twenty-four h after the challenge dose, treatments were administered. The compound treatments were as follows: vehicle, naltrexone (1.3  $\mu\text{mole}/\text{kg}$  or 500  $\mu\text{g}/\text{kg}$ ) or compound **5** (0.036  $\mu\text{mole}/\text{kg}$  or 20  $\mu\text{g}/\text{kg}$ ). Forty-eight h after administration of thiobenzamide or vehicle, the animals were killed and blood was collected in heparin-treated syringes, centrifuged and serum was immediately frozen. Serum was sent to IDEXX Laboratories and serum clinical values were obtained. The mean and standard deviation of the values were calculated and summarized in Table 2.

### **Operant Procedure for Oral EtOH and Supersaccharin Self-Administration**

**Training.** Ethanol or Supersac self-administration training was conducted in standard alcohol vapor chambers (La Jolla Alcohol Research, La Jolla, CA) located in sound-attenuated, ventilated cubicles. Two 35-ml syringes dispensed either EtOH, water or Supersac through plastic tubing into two stainless steel drinking cups mounted 4 cm above the grid floor and centered on the front panel of each chamber. Each drinking cup held 2 reinforcer deliveries (0.1 ml fluid/reinforcer). Two retractable levers were located 4.5 cm to either side of the drinking cups. Fluid delivery and recording of operant responses were controlled by a microcomputer.

Briefly, animals were trained to voluntarily self-administer 10% (w/v) EtOH (n=11) or Supersac (n=11) by the oral route using the saccharin fadeout method (Rassnick et al., 1993) and were tested for their response for EtOH or Supersac solution in a two-lever free choice situation. Once baseline EtOH and Supersac intake were achieved (i.e., when

responding across three consecutive days varied less than 20% and response rates corresponded to pharmacologically relevant blood alcohol levels (BALs)), dose response testing for compound **5** commenced. BALs were measured once per week but never immediately before or after testing as this was deemed too stressful to the animal. Typically, 2-3 days prior to testing BALs were obtained. BAL levels during these experiments were maintained at 150-200 mg percent. To allow for a complete dissipation of any carry-over effects, a one week washout period, where rats were re-baselined during daily 30 min operant sessions, occurred between testing of different doses.

#### **Ethanol self-administration studies.**

P-rats were divided into alcohol binge drinkers (n=11) and Supersac controls (n=11). Prior to two-bottle choice training, all rats were given an initial 2-hour training session during which they were allowed to drink Supersac in a single-bottle situation. Rats were allowed 30-min drinking sessions for 9-14 consecutive days before pharmacological manipulation occurred. Following baseline training, rats were injected subcutaneously (s.c.) with one of several doses of **5**, (0.00312, 0.00625, and 0.0125 mg/kg, 1 ml/kg) 30-min before two-bottle choice test sessions in a within-subjects Latin-square design. Rats were allowed to self-administer every day during this time, but were injected with test compound every other day. Rats were tested during their active cycle.

**Data Analysis.** Statistics, regression analyses and determination of ED<sub>50</sub> values were done using GraphPad Prism® (version 4.02, GraphPad, San Diego, CA). Data of the

effect of opioids on thiobenzamide hepatotoxicity was expressed as mean  $\pm$  standard deviation (SD) and analyzed with the Student *t* test for the difference between two means with a Welch correction. Multiple means were analyzed by a randomized one-way analysis of variance. When the analysis indicated that a significant difference existed, the means of each group were compared by the Student-Newman-Keuls test. In the analyses, the level of significance chosen was  $p < 0.05$ . For alcohol and Supersac self-administration studies, data were simultaneously collected on-line from multiple operant chambers. Results of the operant procedure were reported as mean cumulative number of bar presses  $\pm$  standard error of the mean (SEM) for ethanol or Supersac and normalized for body weight (i.e., g ethanol/kg body weight; ml Supersac/kg body weight). The effects of **5** on alcohol (g/kg) intake and Supersac (ml/kg) intake were analyzed by one-way repeated measures analysis of variance, with a dose of **5** as a within-subjects factor. In general, tests for homogeneity of variance were first conducted on the data. If the scores did not violate the assumption of homogeneity of variance, appropriate analyses of variance (ANOVA) were conducted. Data were analyzed using the StatView statistical package on a PC-Compatible computer. Mixed-design ANOVAs were used with test compound treatments as a within-subjects factor (i.e., repeated measures design for test compound treatment). A priori analysis examining individual test compound doses to vehicle control dose was conducted using paired *t*-tests. Significant test compound effects were defined as having  $p < 0.05$  compared to vehicle-treated rats.

## Results

The chemical synthesis of 17-cyclopropylmethyl-3,14 $\beta$ -dihydroxy-4,5 $\alpha$ -epoxy-6 $\beta$ -[(4'-trimethylfluoro)benzamido]morphinan (compound **5**, Scheme 1) was efficiently



accomplished as described previously (Ghirmai et al., 2009). As a standard for pharmacokinetic studies, a deuterated analog, compound **4**, was efficiently synthesized (Scheme 1). Thus, deuterated compound **4** was synthesized by combining  $\beta$ -naltrexamine, 4-CF<sub>3</sub>-benzoic acid-d<sub>4</sub> and BOP dissolved in anhydrous DCM followed by addition of DIPEA and, after removal of the ester by treatment with potassium carbonate, **4** was obtained in quantitative yield.

As previously reported, compound **5** was evaluated in the presence of opioid receptors using a [<sup>35</sup>S]GTP $\gamma$ S assay (Traynor and Nahorski, 1995). The [<sup>35</sup>S]GTP $\gamma$ S binding data showed that compound **5** was a partial agonist at the  $\mu$ -opioid receptor, and an antagonist of  $\delta$ - and  $\kappa$ -opioid receptors (Ghirmai et al., 2009). In the presence of the NOP receptor, compound **5** had very low affinity and did not stimulate agonist-induced GTP $\gamma$ S binding. Compound **5** was found to potently decrease basal binding at NOP. Compound **5** was a high affinity compound that showed low or partial agonist activity in the GTP $\gamma$ S binding experiment and was tested for inhibition of agonist-induced GTP $\gamma$ S binding at each opioid receptor. Compound **5** produced potent inhibition at both  $\kappa$ - and NOP-receptors, modest inhibition at  $\delta$ -receptor, but not at the  $\mu$ -receptor. Compound **5** was shown to possess potent antagonism for the  $\kappa$ -opioid and NOP-receptors and was taken forward for *in vivo* studies. As described below, further kinetic analysis was done to characterize the pharmaceutical properties of compound **5**.

### **Metabolic Stability and Pharmacokinetics**

As reported previously, the metabolic stability of compound **5** was examined in the presence of rat, mouse and human liver preparations plus the appropriate NADPH

generating system (Ghirmai et al., 2009). Compared to nalmefene, compound **5** was quite metabolically stable. In the presence of mouse or human liver microsomes, compound **5** possessed half life values in excess of 112 min and was judged to be quite metabolically stable. In the presence of rat liver microsomes, overall, **5** was somewhat less metabolically stable, but the half life values observed did not preclude evaluation of the compounds *in vivo*.

Evaluation of the inhibition of selective functional activity of CYP previously reported (Ghirmai et al., 2009) was done for **5** as a control on the apparent metabolic stability. The CYP enzyme assays were done using standard conditions as previously described (Denton et al., 2004). Compared to nalmefene, compound **5** possessed less inhibitory potency against the CYPs studied (i.e., CYP-3A4, -2B6, -2C9, -2C19 and -2D6). A possible exception was CYP2C19 that appeared to be more sensitive than nalmefene to inhibition by **5**. Because no significant inhibition of CYP was observed and based on the low plasma concentration of **5** observed (i.e., 2-8 ng/ml, Table 1) it is unlikely compound **5** inhibits CYP and alcohol metabolism *in vivo* at the doses used in this study. This is based on the well-recognized relationship (i.e.,  $I/K_i$ ) that predicts the potential for *in vivo* interaction (Wienkers and Heath, 2005). If  $I/K_i$  is greater than 1 then a significant interaction is predicted. In the case herein, the  $I/K_i$  ratio is = 0.0003 assuming a  $K_i$  of 10  $\mu$ M. Therefore, no significant interaction is predicted. At the concentrations that are effective at decreasing alcohol self administration (i.e., 5-10  $\mu$ g/kg), there is virtually no effect of **5** on CYP-mediated alcohol metabolism. Accordingly, compound **5** was advanced to pharmacokinetic studies.

#### ***In Vivo* Studies with Compound 5.**

The pharmacokinetics (PK) of compound **5** was examined in male Sprague Dawley rats by the i.v. (i.e., 2 doses, 20 and 50  $\mu\text{g}/\text{kg}$ ) and oral (one dose, 200  $\mu\text{g}/\text{kg}$ ) routes of administration. The doses were chosen to mimic the situation in efficacy studies and still be above the lowest limit of detection (20  $\text{pg}/\text{ml}$  in plasma) by LCMS-MS. Serum was extracted and analytes were determined by LCMS-MS. The data of Table 1 shows the PK parameters for compound **5**. The preliminary PK studies of the *para*-bromophenyl analog of **5** (i.e., compound **3**, Scheme 1) have been previously reported (Ghirmai et al., 2009) and are in general agreement with the results described below for **5**.

The hydrochloride salt of **5** was administered to two groups of three rats via the oral (200  $\mu\text{g}/\text{kg}$ ) or i.v. (20  $\mu\text{g}/\text{kg}$ ) routes of administration. After oral administration of **5**, the  $T_{\text{max}}$  was 120 min and the apparent  $T_{1/2}$  was 3.4 h. After i.v. administration of **5**, the  $T_{\text{max}}$  was 5 min and the  $T_{1/2}$  was 114 min. A summary of the pharmacokinetic parameters is listed in Table 1. The bioavailability was calculated at 11%. Previously, reported data showed that the brain tissue:plasma ratio of the closely related *para*-bromophenyl analog **3** (i.e., a ratio of 2.3:1) was adequate to proceed with *in vivo* studies (Ghirmai et al., 2009).

Before extensive efficacy studies were conducted, preliminary toxicology studies were undertaken to help establish the safety of **5**. Range-finding toxicology studies were done in male Sprague Dawley rats. Compound **5** was very well tolerated in rats. Doses as great as 4  $\text{mg}/\text{kg}$  (oral) of **5** did not show any adverse effects and clinical chemistry analysis of plasma revealed no liver or kidney toxicity. A dose of 4  $\text{mg}/\text{kg}$  of **5** is a dose that is 200-fold greater than an estimated efficacious dose. Chronic dosing of compound **5** for 7 days at a dose of 2  $\text{mg}/\text{kg}$  (i.e., a dose that is 100-fold greater than an estimated

efficacious dose) showed no signs of clinical toxicity on the basis of analysis of plasma clinical chemistry. Compared to rats treated with vehicle alone, 7 day dosing of compound **5** at 2 mg/kg caused no apparent liver or kidney toxicity.

### **Effect of compound 5 or Naltrexone on an animal model of acute hepatotoxicity**

The effect of **5** or naltrexone on the relative hepatotoxicity of co-administered thiobenzamide to rats was determined. As shown in Table 2, thiobenzamide (2 mmole/kg, i.p.) produced significant hepatotoxicity at 48 hours post-administration compared with vehicle (i.e., 17.8-fold and 12.4-fold increase in hepatotoxicity, respectively) on the basis of serum SGPT and SGOT values. Administration of **5** (20  $\mu$ g/kg, i.p.) 24 h after thiobenzamide (2 mmole/kg in corn oil, i.p.) showed a decrease in SGPT and SGOT values (i.e., almost a 4-fold and 0.4-fold, respectively, decrease in hepatotoxicity compared with thiobenzamide alone). In contrast, administration of naltrexone (500  $\mu$ g/kg, i.p.) 24 h after thiobenzamide exacerbated the hepatotoxicity of thiobenzamide. Compared to thiobenzamide alone, administration of thiobenzamide and then naltrexone increased SGPT and SGOT levels over 21-fold and 17.8-fold, respectively. Compared to administration of naltrexone, administration of compound **5** twenty-four h after thiobenzamide significantly decreased hepatotoxicity of thiobenzamide ( $p = 0.0034$ ). The hepatoprotective effect of **5** on thiobenzamide hepatotoxicity was statistically significant compared to the lack of any hepatoprotective effect of naltrexone on thiobenzamide hepatotoxicity ( $p = 0.0005$ ). The hepatoprotective effect of **5** on thiobenzamide hepatotoxicity as judged by SGOT values was nearly statistically significant compared to the lack of any hepatoprotective effect of naltrexone on thiobenzamide hepatotoxicity ( $p = 0.055$ ). There was no statistically significant

difference of treatment by **5** or naltrexone on the toxicity of thiobenzamide on the basis of serum albumin or BUN values.

### ***In Vivo* Alcohol Self-Administration Studies**

Previously, we showed that **5** possessed potent effects on ethanol (EtOH) intake in non-dependent Wistar rats trained to self-administer a 10 % (w/v) ethanol solution, utilizing operant techniques (Ghirmai et al., 2009). As a positive control, nalmefene hydrochloride was also examined. Previous studies showed that **5**, naltrexone and nalmefene inhibited alcohol self-administration with ED<sub>50</sub> values of 0.019, 0.5 and 0.040 mg/kg, respectively, in the Wistar rat model. Because compound **5** showed considerable potency at inhibition of alcohol self-administration it was studied further in alcohol-preferring rats (i.e., P-rats). We based the dose selection of **5** in P-rats on the outcome of the testing of compound **5** in non-dependent normal Wistar rats.

Results showed that P-rats voluntarily and orally self-administered amounts of alcohol to produce blood alcohol levels on average of 0.071 g % following 30-minute self-administration sessions. The average sweetened alcohol solution intake in P-rat vehicle controls during drug testing was 9.0 ml (1.5 g/kg) in the absence of food or water deprivation. Compound **5** was administered s.c. in a Latin Square Design dose range study and showed significant efficacy. A detailed study employing **5** from 0.003125 to 0.0125 mg/kg showed that the compound was efficacious at inhibiting sweetened alcohol self-administration in non-dependent (air exposed) and EtOH-dependent (ethanol vapor exposed) P-rats (Figure 1). Compound **5** pretreatment dose-dependently decreased intake of sweetened alcohol solution by P-rats (Figure 1). Analysis revealed that **5** at 0.00312, 0.00625 and 0.0125 mg/kg doses significantly suppressed alcohol intake in alcohol-

dependent P-rats ( $p < 0.05$ ). Analysis revealed that **5** at 0.00625 and 0.0125 mg/kg doses significantly suppressed alcohol intake in alcohol-nondependent P-rats ( $p < 0.05$ ) (Figure 1).

To test whether the effect of compound **5** was selective for sweetened ethanol, the effect of **5** on self-administration of water (Figure 2) was examined. Treatment with compound **5** did not have an overall effect on the self-administration of water compared with vehicle. In control alcohol-dependent P-rats that consumed water, analysis did not reveal any significant effect of compound **5** dose on water intake (Figure 2). In control alcohol-nondependent P-rats that consumed water, analysis did not reveal any significant effect of compound **5** dose on water intake except at the 0.0125 mg/kg dose (Figure 2). Data represented mean responses for EtOH following compound **5** (0.0-0.0125 mg/kg) administration in non-dependent controls (air exposed, n=8) and ethanol-dependent (EtOH vapor exposed, n=10) P-rats after 6 h withdrawal. Compound **5** produced decreases in EtOH self-administration at 0.00625 and 0.0125 mg/kg compared to air (white bars) and EtOH vapor-exposed ((black bars) vehicle controls;  $*p < 0.05$ ) (Figure 1). The ED<sub>50</sub> for compound **5** in EtOH-dependent (black bars) P-rats was estimated to be 0.0044 mg/kg, and in non-dependent rats (white bars) was estimated to be 0.05 mg/kg, using linear regression methods.

To further examine the effect of **5** on alcohol self-administration, compound **5** was examined on alcohol self-administration in Binge-like P-rats. The term Binge-like P-rats was used because the animals did not quite achieve BALs that are normally associated with Binge drinking P-rats (i.e., Binge-like P-rats attained 1.2-1.4 g/kg EtOH in a 30 min session

whereas Binge-P-rats generally achieve 1.5 g/kg EtOH in a 30 min session). Compound **5** was administered s.c. in a Latin Square Design dose range study and showed significant efficacy. Doses of **5** from 0.00312 to 0.0125 mg/kg showed that compound **5** inhibited Supersac-sweetened alcohol self-administration in Binge-like P-rats (Figure 3). Compared with vehicle, analysis showed that at all doses of **5** examined, compound **5** significantly suppressed Binge-like alcohol intake in P-rats ( $p < 0.05$ ). The ED<sub>50</sub> was estimated to be 0.008 mg/kg in Binge-like P-rats (Figure 3). To test whether the effect of compound **5** was selective for Supersac-sweetened ethanol, the effect of **5** on self-administration of Supersac (Figure 4) was examined. In control animals that only consumed Supersac, analysis did not reveal any significant effect of **5** for the doses examined on Supersac intake (Figure 4).

Next, the effect of **5** on alcohol self-administration in Binge-like Wistar rats was examined. Compound **5** was administered s.c. in a Latin Square Design dose range study and showed significant efficacy. Doses of **5** from 0.00312 to 0.0125 mg/kg showed that compound **5** inhibited Supersac-sweetened alcohol self-administration in Binge-like Wistar rats (Figure 5). Compared with vehicle, analysis showed that 0.00625 and 0.0125 mg/kg of **5**, compound **5** significantly suppressed Binge-like alcohol intake in Wistar rats ( $p < 0.05$ ). The ED<sub>50</sub> was estimated to be 0.012 mg/kg in Binge-like Wistar rats (Figure 5). To test whether the effect of compound **5** was selective for Supersac-sweetened ethanol, the effect of **5** on self-administration of Supersac was examined (Figure 6). In control animals that only consumed Supersac, analysis did not reveal any significant effect of **5** for the doses examined on Supersac intake except 0.0125 mg/kg (Figure 6).

## Discussion

Replacement of the C-6 ketone group of naltrexone with an aryl amide substituent as in **5** afforded a compound that inhibited the self-administration of alcohol in P-rats and in Binge-like P rats. Compound **5** is a reversible, relatively short-acting kappa antagonist. Compared to nor-BNI, **5** is much more drug-like and much shorter-acting. Compound **5** is lipophilic (i.e.,  $\log P = 3.73$ ) and based on its pharmacokinetics rapidly leaves the bloodstream and gets into the brain. Because **5** does not possess a propensity for auto-oxidation that nor-BNI shows, its residence time and duration of action in the brain is also considerably shorter. Consequently, the effect of **5** on opioid receptors (i.e., binding, receptor desensitization etc.) must be fundamentally different than for nor-BNI and other long-acting kappa antagonists. Animals treated with **5** showed no residual effects after 24 hours and appeared to be normal from a morphological and behavioral standpoint. Administration of a dose of **5** to rats 500-fold greater than a dose required for an ED<sub>50</sub> dose for inhibition of alcohol self-administration did not show any detectable hepatotoxicity or renal toxicity or other toxicity. Chronic dosing of **5** in rats at 2 mg/kg for 7 days did not cause any detectable hepatotoxicity or other untoward clinical chemical abnormalities on the basis of analysis of plasma clinical chemical parameters taken at 7 days. The conclusion is that compound **5** is a relatively fast-acting opioid that is safe and relatively well-tolerated in small animals.

Compared to naltrexone (ED<sub>50</sub> 500 µg/kg) or nalmeferne (ED<sub>50</sub> 40 µg/kg), compound **5** (ED<sub>50</sub> 19 µg/kg) is a more potent inhibitor of alcohol self-administration in non-dependent normal Wistar rats (Ghirmai et al., 2009). Using P-rat and Binge-like P-rat animals herein we showed that **5** was even more efficacious at inhibiting alcohol self-administration (i.e., ED<sub>50</sub> 4-5 µg/kg and ED<sub>50</sub> 8 µg/kg, respectively). These data show



that under a variety of experimental conditions compound **5** is an effective antagonist of responding maintained by large amounts of alcohol. We attribute this increase in efficacy as due to potent  $\kappa$  opioid antagonism compared with naltrexone or nalmefene. As described above, it is also likely due to improved pharmaceutical properties of the compound and decreased interaction with the prominent CYP drug metabolizing system. It may be that attenuation of the inhibitory potency of **5** toward CYP (Ghirmai et al., 2009) contributes to the safety of **5**. Compared to naltrexone, **5** showed decreased interaction with CYP and this may in part explain some of the metabolic stability observed for **5** and related compounds (Ghirmai et al., 2009; MacDougall et al., 2004) as well as some of the hepatoprotective properties. Substitution of an aryl amide moiety at the C-6 position of  $\beta$ -naltrexamine may also explain some of the hepatoprotective effects of **5**. For example, at a dose of naltrexone that represents the ED<sub>50</sub> for inhibition of alcohol self-administration (i.e., ED<sub>50</sub> 500  $\mu$ g/kg), naltrexone exacerbates the hepatotoxicity of thiobenzamide in a rat model of hepatotoxicity. In contrast, at a dose of **5** that represents its ED<sub>50</sub> (i.e., ED<sub>50</sub> 20  $\mu$ g/kg), compound **5** protects against the hepatotoxicity of thiobenzamide in rats challenged with thiobenzamide, a potent hepatotoxin. Exacerbation of the hepatotoxicity of thiobenzamide by naltrexone is of considerable concern because, generally, the liver of individuals that abuse alcohol is severely compromised. It may be that decreasing the affinity of opioid derivatives for metabolic enzymes and increasing the metabolic stability results in compounds with less potential for increasing hepatotoxicity.

In a previous study (Ghirmai et al., 2009) we showed that **5** decreased alcohol self-administration in normal Wistar rats. We proposed the mechanism of action of **5** was

working at least in part as a kappa opioid receptor antagonist. In good agreement with those results, we show herein that **5** is very effective to decrease alcohol self-administration in a Binge-like P-rat model as well as a Binge-like Wistar rat model. Moreover, the effect of **5** to decrease alcohol self-administration was selective because at efficacious doses, compound **5** did not have an effect on water or Supersac consumption. This is important because some opioid receptor antagonists decrease both ethanol and sucrose intake in rats (Pastor et al., 2006) or inhibit energy-rich food consumption (Reid et al., 1985). It may be that opioid receptor antagonists prevent central reward mechanisms that may share common neural substrates responsible for the development of alcohol dependence (Yeomans et al., 2002).

On the basis of previously published opioid receptor binding data, it appears that **5** works as a partial agonist at the  $\mu$  receptor and an antagonist at the  $\delta$  and  $\kappa$  opioid receptors. But the potency against the  $\kappa$  opioid receptor is much greater than that of the  $\delta$  opioid receptor and at the concentration of **5** that is efficacious *in vivo* at inhibiting alcohol self-administration, we conclude  $\kappa$  is the pharmacologically prominent receptor. The finding from *in vivo* studies that **5** potently inhibits alcohol self-administration in P-rats and Binge-like Wistar rats supports the idea that antagonism of  $\kappa$  opioid receptors might be of utility for full alcohol cessation functional activity. However, compared to naltrexone, the *in vivo* efficacy of **5** may not only be dependent on interaction with the  $\kappa$  opioid receptor but also partial agonism of the  $\mu$  opioid receptor. Presumably, the profile of opioid receptor binding coupled with the drug-like properties of **5** contributes to the optimal functional activity as an alcohol self-administration inhibition agent *in vivo*. This is in agreement with recent studies that show that an opioid with strong  $\kappa$  opioid receptor

antagonism albeit possessing some opioid agonism (i.e., nalmefene) (Bart et al., 2005) was more effective at inhibition of alcohol-self administration than an opioid with broad opioid receptor antagonism (i.e., naltrexone) (Walker and Koob, 2008). Consequently, compounds such as **5** and related agents may represent an exciting lead for developing the next generation of opioid compounds useful in the treatment of alcohol abuse.

### **Acknowledgements**

The authors thank Drs. Jarek Kalisiak and Marion Lanier for their help with some of the synthetic and analytical work described herein. The authors thank Dr. Sigeng Cheng for help with some of the animal work. We thank Michael Ly and David Johnson at Microconstants, Inc., for the pharmacokinetic analytical work.

### **Authorship Contribution**

Participated in research design: Cashman, Azar

Conducted experiments: Cashman, Azar

Contributed new reagents or analytical tools: Cashman

Performed data analysis: Cashman, Azar

Wrote or contributed to the writing of the manuscript: Cashman, Azar

## References

- Anton, R.F., Moak, D.H., Waid, L.R., Latham, P.K., Malcolm, R.J. and Dias, J.K. (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. *Am. J. Psychiatry*, **156**, 1758-1764.
- Bart, G., Schluger, J.H., Borg, L., Ho, A., Bidlack, J.M., Kreek, M.J. (2005) Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? *Neuropsychopharmacology* **30**, 2254-2262.
- Benjamin, D., Grant, E.R. and Pohorecky, L.A. (1993) Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake freely moving rats. *Brain Res.* **621**, 137-140.
- Biggs, T.A.G. and Myers, R.D. (1998) Naltrexone and amperozide modify chocolate and saccharin drive high alcohol-preferring P-rats. *Pharm Biochem Behavior* **60** (2), 407-413.
- Bondon, A., Macdonald, T.L., Harris, T.M. and Guengerich, F.P. (1989) Oxidation of cycloalkylamines by cytochrome P-450. Mechanism-based inactivation, adduct formation, ring expansion, and nitrene formation. *J Biol Chem.* **264**, 1988-1997.
- Bouza, C., Angeles, M., Munoz, A. and Amate, J.M. (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. *Addiction* **99**, 811-828.
- Brewer, C. and Wong, V.S. (2004) Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. *Addict. Biol.* **9**(1), 81-87.

- Brunelle, A., Bi, Y.A., Lin, J., Russell, B., Luy, L., Berkman, C. and Cashman J.R. (1997) Characterization of two human flavin-containing monooxygenases (form 3) enzymes expressed in *Escherichia coli* as maltose binding protein fusions. *Drug Metab. Dispos.* **25**, 854-860.
- Cashman, J.R., Hanzlik, R.P. (1981) Microsomal Oxidation of Thiobenzamide. A Photometric Assay for the Flavin-Containing Monooxygenase. *Biochem. Biophys. Res. Commun* **98**, 147–153. [PubMed: 7213381]
- Cashman, J.R., Hanzlik, R.P. (1982) Oxidation and Other Reactions of Thiobenzamide Derivatives of Relevance to Their Hepatotoxicity. *J. Org. Chem.*; **47**, 4745–4650.
- Cashman, J.R. and MacDougall, J.M. (2005) Dynamic medicinal chemistry in the elaboration of morphine-6-glucuronide analogs. *Curr. Topics Med. Chem.* **5**, 585-594.
- Croop, R.S., Faulkner, E.B. and Labriola, D.F. (1997) The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. *Arch Gen Psychiatry.* **54**, 1130-1135.
- Denton, T.T., Zhang, X–D. and Cashman, J.R. (2004) Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. *Biochem. Pharmacol.* **67**, 751-756.
- Doss, G.A. and Baillie, T.A. (2006) Addressing metabolic activation as an integral component of drug design. *Drug Metab Rev.* **38**, 641-649.
- Ghirmai, S., Azar, M.R., Polgar, W.E., Berzetei-Gurske, I. and Cashman, J.R. (2008) Synthesis and Biological Evaluation of  $\alpha$ - and  $\beta$ -6-Amido Derivatives of 17-

Cyclopropylmethyl-3, 14 $\beta$ -dihydroxy-4, 5  $\alpha$ -epoxymorphinan: Potential Alcohol-Cessation Agents. *J. Med. Chem.* **51**, 1913-1924.

Ghirmai, S., Azar, M.R. and Cashman, J.R. (2009) Synthesis and Pharmacological Evaluation of 6-Naltrexamine Analogs for Alcohol Cessation. *Bioorg. Med. Chem.* **17**, 6671-6681.

Gianoulakis, C., Krishnan, B. and Thavundayil, J. (1996) Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. *Arch. Gen. Psychiatry* **53**, 250-257.

Gilpin, N.W., Richardson, H.N. and Koob, G.F. (2008) Effects of CRF1-Receptor and Opioid-Receptor Antagonists on Dependence-Induced Increases in Alcohol Drinking by Alcohol-Preferring (P) Rats. *Alcoholism: Clinical and Experimental Research*, **32**, 1535-1542.

Grisel, J.E., Grahame, N.J., Mogil, J.S., Belknap, J.K. and Low, M.J. (1995) Decreased voluntary ethanol consumption in transgenic mice lacking  $\beta$ -endorphin. *Soc. Neurosci. Abstr.* **21**,1699.

Hanzlik, R.P., and Cashman, J.R. (1983) Microsomal Metabolism of Thiobenzamide and Thiobenzamide-S-oxide. *Drug Metab. Dispos.*; **11**,210–215.

Hanzlik, R.P., Cashman, J.R., and Traiger, G.J. (1980) Relative Hepatotoxicity of Substituted Thiobenzamides and Thiobenzamide-S-oxides in the Rat. *Toxicol. Appl. Pharmacol.* **55**, 260–272. [PubMed: 7423516]

- Hanzlik, R.P., Vyas, K.P., Traiger, G.J. (1978) Substituent Effects on the Hepatotoxicity of Thiobenzamide Derivatives in the Rat. *Toxicol. Appl. Pharmacol.* **46**, 685–694.  
[PubMed: 746555]
- Herz, A. (1997) Endogenous opioid systems and alcohol addiction. *Psychopharmacology* **129**, 99-111.
- Heyser, C.J., Moc, K. and Koob, G.F. (2003) Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. *Neuropsychopharmacology*. **28**,1463-1473.
- Heyser, C.J., Roberts, A.J., Shulteis, G. and Koob, G.F. (1999) Central administration of an opiate antagonist decreases oral ethanol self-administration in rats. *Alcohol. Clin Exp Res.* **23**, 1468-1476.
- Heyser, C.J., Schulteis, G. and Koob, G.F. (1997) Increased ethanol self-administration after a period of imposed ethanol deprivation in rats trained in a limited access paradigm. *Alcohol. Clin Exp Res.* **21**, 784-791.
- Holter, S.M. and Spanagel, R. (1999) Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats. *Psychopharmacology (Berl)*, **145**, 360-369.
- Horan, P., Taylor, J. Yamamura, H.I., and Porreca, F. (1992) Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. *J Pharm. Exper. Ther.* **260**(3), 1237-1243.

- James, R.C., Goodman, D.R. and Harbison, R.D. (1982) Hepatic glutathione and hepatotoxicity: changes induced by selected narcotics. *J. Pharmacol. Exper. Ther.* **221**(3), 708-714.
- Ji, D., Gilpin, N.W., Richardson, H.N., Rivier, C.L., and Koob, G.F. (2008) Effects of naltrexone, duloxetine and a corticotrophin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. *Behav. Pharmacol.* **19**(1), 1-12.
- June, H.L., Cummings, R., Eiler W.J. 2nd., Foster K.L., McKay, P.F., Seyoum, R., Garcia, M., McCane, S., Grey, C., Hawkins, S.E., Mason, D. (2004) Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol-preferring (P) rats. *Neuropsychopharmacology.* **29**(2), 285-299.
- June, H.L., Grey, C., Warren-Reese, C., Durr, L.F., Ricks-Cord A., Johnson, A., McCane, S., Williams, L.S., Mason, D., Cummings, R., Lawrence, A. (1998) The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. *Alcohol Clin Exp Res.* **22**, 2174-2185.
- Li, T.K., Lumeng, L., McBride, W.J., Murphy, J.M. (1987) Rodent lines selected for factors affecting alcohol consumption. *Alcohol Alcoholism* **1**, 91-96.
- Lowry, T.H., and Richardson, K.S. (1987) In "Mechanism and Theory in Organic Chemistry", Chapter 2, pg 127, Harper and Row, Publishers, 3<sup>rd</sup> Ed., New Your, NY.
- MacDougall, J.M., Zhang, X.D., Polgar, W.E., Khroyan, T.V., Toll, L. and Cashman, J.R.



- (2004) Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide. *J Med Chem.* **47**,: 5809-5815.
- Mason, B.J., Salvato, F.R., Williams, L.D., Ritvo, E.C. and Cutler, R.B. (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. *Arch Gen Psychiatry* **56**, 719-724.
- Mitchell, J.E., Morley, J.E., Levine, A.S., Hatsukami, D. Gannon, M., Pfohl, D. (1987) High-dose naltrexone therapy and dietary counseling for obesity. *Biol. Psychiatry* **22**(1), 35-42.
- Mohamed, M.S., and Portoghese, P.S. (1986) Stereoselectivity of the Reduction of Naltrexone Oxime with Borane. *J. Org. Chem.* **51**, 105-106.
- Munro, T.A., Berry, L.M., Van't Veer, A., Beguin, C., Carroll, F.I., Zhao, Z., Carlezon, W.A., and Cohen, B.M. (2012) Long-acting kappa opioid antagonists nor-BNI, GNTI and JDtIc: Pharmacokinetics in mice and lipophilicity. *BMC Pharmacol.* **12**(5) <http://dx.doi.org/10.1186/1471-2210-12-5>
- Osa, Y., Ida, Y., Fujii, H., Nemoto T., Hasebe, K., Momen, S., Mochizuki, H., Nagase, H. (2007) Catalytic aerobic oxidation of nor-binaltorphimine (nor-BNI) analogs without 4,5-epoxy bridge affords a more selective ligand for kappa opioid receptor than the representative kappa antagonist nor-BNI. *Chem. Pharm. Bull (Tokya)* **55**(10), 1489-1493.
- Oslin, D.W., Berrettini, W.H. and O'Brien, C.P. (2006) Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone *Addict. Biol.* **11**, 397-403.
- Pastor, R. and Aragon, C.M. (2006) The role of opioid receptor subtypes in the

development of behavioral sensitization to ethanol. *Neuropsychopharmacol.* **31**, 1489-1499.

Pettinati, H.M., O'Brien, C.P., Rabinowitz, A.R., Wortman, S.P., Oslin, D.W., Kampman, K.M. and Dackis, C.A. (2006) The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. *J. Clin. Psychopharmacol.* **21**, 610-625.

Rassnick, S., Pulvirenti, L., Koob, G.F. (1993) SDZ-205,152, a novel dopamine receptor agonist, reduces oral ethanol self-administration in rats. *Alcohol* **10**, 127-132.

Reid, L.D. (1985) Endogenous opioid peptides and regulation of drinking and feeding. *Am. J. Clin. Nutr.* **42**, 1099-1132.

Roberts, A.J., McDonald, J.S., Heyser, C.J., Kieffer, B.L., Matthes, H.W., Koob, G.F. and Gold, L.H. (2000)  $\mu$ -Opioid Receptor Knockout Mice Do Not Self-Administer Alcohol. *J. Pharmacol. Exp. Ther.* **293**,1002-1008.

Roberts, A.J., Smith, A.D., Weiss, F., Rivier, C. and Koob, G.F. (1998) Estrous cycle effects on operant responding for ethanol in female rats. *Alchol Clin Exp Res.* **22**,1564-1569.

Roozen, H.G., deWaele, R., van der Windt, D.A., van der Brink, W., de Jong, C.A. and Kerkhof, A.J. (2006) A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. *Eur. Neuropsychopharmacol.* **16**, 311-323.

Sax, D.S., Kornetsky, C., and Kim, A. (1994) Lack of hepatotoxicity with naltrexone

treatment. *J. Clin. Pharmacol.* **34**(9), 898-901

Stevens, W.C., Jones, R.M., Subramanian, G., Metzger, T., Ferguson, D.M. and Portoghese, P.S. (2000) Potent and Selective Indolomorphinan Antagonists of the Kappa-Opioid Receptor. *J. Med. Chem.* **43**, 2759-2769.

Stromberg, M.F., Mackler, S.A., Volpicelli, J.R., and O'Brien, C.P. (2001) Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. *Alcohol* **23**, 109-116.

Tabakoff, B. and Hoffman, P.L. (1983) Alcohol interactions with brain opiate receptors. *Life Sci.* **32**, 197-204.

Traynor, J.R. and Nahorski, S.R. (1995) Modulation by  $\mu$ -opioid agonists of guanosine-5'-O-(3-[<sup>35</sup>S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. *Mol. Pharmacol.* **47**, 848-854.

Tullman, R.H. and Hanzlik, R.P. (1984) Inactivation of cytochrome P-450 and monoamine oxidase by cyclopropylamines. *Drug Metab Rev.* **15**, 1163-1182.

Ulm, R.R., Volpicelli, J.R., and Volpicelli, L.A., (1995) Opiates and alcohol self-administration in animals. *J. Clin. Psychiatry* **56**, 5-14.

Walker, B.M. and Koob, G.F. (2008) Pharmacological evidence for a motivational role of  $\kappa$ -opioid systems in ethanol dependence. *Neuropsychopharm.* **33**, 643-652.

Walker, B.M., Zorrilla, E.P. and Koob, G.F. (2011) Systemic  $\kappa$ -opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. *Addiction Biology*, **16**, 116-119.

Wienkers, L.C. and Heath, T.G. (2005) Predicting *in vivo* drug interactions from *in vitro* drug discovery data. *Nature Reviews Drug Discovery* **4**, 825-833.

Weiss, F., Mitchiner, M., Bloom, F.E., Koob, G.F. (1990) Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocryptine and methysergide. *Psychopharmacol.* **101**(2), 178-186.

Yano, J.K., Denton, T.T., Cerny, M.A., Zhang, X., Johnson, E.F. and Cashman, J.R. (2006) Synthetic inhibitors of cytochrome P-450 2A6: Inhibitory activity, difference spectra, mechanism of inhibition and protein cocrystalization. *J. Med. Chem.* **49**, 6987-7001.

Yen, M-H., Ko, H-C., Tang, F-I., Lu, R-B., and Hong, J-S. (2006) Study of hepatotoxicity of naltrexone in the treatment of alcoholism. *Alcohol* **38**(2), 117-120.

Yeomans, M.R., and Gray, R.W. (2002) Opioid peptides and the control of human ingestive behavior. *Neurosci. Biobehavioral Rev.* **26**, 713-728.

**Footnote**

This work was financially supported by a grant from the National Institutes of Health [Grant AA016029 to MA].

## Legends for Figures and Scheme

**Scheme 1.** Chemical structures of compounds **1-5**.

**Figure 1.** Operant lever presses for ethanol by alcohol-dependent (black bars) and alcohol-nondependent (white bars) P-rats following injection of compound **5** doses (0, 0.00312, 0.00625, 0.0125 mg/kg). Operant tests occurred 6 hours following termination of vapor exposure (i.e., 6 hours withdrawal). \* $p < 0.05$  significant difference from vehicle condition in alcohol-dependent or alcohol-nondependent control P-rats.

**Figure 2.** Operant lever presses for water by alcohol-dependent (black bars) and alcohol-nondependent (white bars) P-rats following injection of compound **5** (0, 0.00312, 0.00625, 0.0125 mg/kg). Operant tests occurred 6 hours following termination of vapor exposure (i.e., 6 hours withdrawal). \* $p < 0.05$  significant difference from vehicle condition in alcohol-dependent or alcohol-nondependent control P-rats.

**Figure 3.** Mean  $\pm$  SEM intake (g/kg) of Supersac sweetened (3% glucose + 0.125% saccharin) 10% (w/v) alcohol solution by P-rats in the alcohol binge-like group (n=12) following pretreatment with one of four doses of compound **5** (0, 0.00312, 0.00625, 0.0125 mg/kg). \* $p < 0.05$ , significant difference from vehicle condition.

**Figure 4.** Mean  $\pm$  SEM Supersac intake (ml/kg) by Supersac controls P-rats (n=12) in the following pretreatment with one of four doses of compound **5** (0, 0.00312, 0.00625,

0.0125 mg/kg). Data revealed no non-specific effects of on fluid intake following pretreatment with compound **5**.

**Figure 5.** Mean  $\pm$  SEM intake (g/kg) of Supersac sweetened (3% glucose + 0.125% saccharin) 10% (w/v) alcohol solution by Wistar rats in the alcohol binge-like group (n=12) following pretreatment with one of four doses of compound **5** (0, 0.00312, 0.00625, 0.0125 mg/kg). \* $p < 0.05$ , significant difference from vehicle condition.

**Figure 6.** Mean  $\pm$  SEM Supersac (3% glucose + 0.125% saccharin) intake (ml/kg) by Supersac control Wistar rats (n=12) following pretreatment with one of four doses of compound **5** (0, 0.00312, 0.00625, 0.0125 mg/kg). \* $p < 0.05$ , significant difference from vehicle condition.

**Table 1.** Pharmacokinetic parameters for lead compound 5.

<b>Route</b>	<b>Dose (<math>\mu\text{g}/\text{kg}</math>)</b>	<b>C<sub>max</sub> (<math>\text{pg}/\text{ml}</math>)</b>	<b>T<sub>max</sub> (hr)</b>	<b>AUC (<math>\text{pg} \times \text{hr}/\text{ml}</math>)</b>	<b>CL/F (<math>\text{L}/\text{hr}/\text{kg}</math>)</b>	<b>T<sub>1/2</sub> (hr)</b>
iv	20	2230	0.08	1704	11.73	1.9
iv	50	7790	0.08	3559	14.05	1.5
Oral	200	89	2	578	346	3.4





**Table 2. Effect of Kappa Antagonism on the Hepatotoxicity of Thiobenzamide**

<b>Condition</b>	<b>Alkaline Phosphatase<sup>1</sup></b>	<b>SGPT (ALT)</b>	<b>SGOT (AST)</b>	<b>Albumin</b>	<b>BUN</b>
Control	227.3 ± 13.8	44.7 ± 8.7	82.3 ± 27.6	2.9 ± 0.1	23.3 ± 3.2
Thiobenzamide alone	150.5 ± 55.6*	798 ± 447.1*	1021 ± 775.8*	2.6 ± 0.3	66.2 ± 34.9*
Thiobenzamide + Compd <b>5</b>	122.5 ± 18.8	613.7 ± 349.2 <sup>+</sup>	993 ± 172.2	2.8 ± 0.4	43.2 ± 7.4
Thiobenzamide + Naltrexone	169 ± 84.5	1749.8 ± 245.1 <sup>#</sup>	1461.8 ± 312.3	2.5 ± 0.2	57.8 ± 23.9

<sup>1</sup> Mean ± the standard deviation of values from six animals.


\* Control vs. Thiobenzamide (274 mg/kg) Alone. The level of significance chosen was P-values < 0.05

+ Thiobenzamide (274 mg/kg) Alone vs. Thiobenzamide + Naltrexone (500 µg/kg). The level of significance chosen was P-values < 0.05


# Thiobenzamide (274 mg/kg) + Compound **5** (20 µg/kg) vs. Thiobenzamide (274 mg/kg) + Naltrexone (500 µg/kg). The level of significance chosen was P-values < 0.05.




Scheme 1




**1**  
**Naltrexone**




**2**  
**Nalmefene**



**3**



**4**



**5**




Figure 1

Mean water reinforcements (+/- SEM)





Figure 2

**EtOH intake ( g/kg, +/- SEM)**



**Figure 3**





Figure 4



**EtOH intake ( g/kg, +/- SEM)**



**Figure 5**

